The findings add to growing evidence that obesity behaves like a chronic disease rather than a short-term condition that can be permanently reversed after temporary treatment
Current frequently used GLP-1-based medications include: Ozempic (semaglutide) : A GLP-1 receptor agonist approved for type 2 diabetes management
Successive case reports confirmed the beneficial effects of liraglutide in obese PsO patients without T2DM (52), and a subsequent trial demonstrated marked improvements in PsO symptoms within a few days of treatment, regardless of significant weight loss (50), a result which was later confirmed in other studies (53, 54)
The following search algorithm was applied: ((GLP-1 receptor agonist OR glucagon-like peptide-1 receptor agonist OR GIP receptor agonist OR glucose-dependent insulinotropic polypeptide OR liraglutide OR semaglutide OR dulaglutide OR tirzepatide) AND (body composition OR fat mass OR muscle mass OR lean mass OR adiposity OR body fat OR sarcopenia)) AND (clinical trial OR study OR randomized controlled trial OR RCT OR intervention study)
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Brain endothelial cells regulate glucagon-like peptide 1 entry into the brain via a receptor-mediated process
